Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Q2 FY26 Earnings Presentation
8 slides from Curvebeam Ai's earnings presentation, Jan 29, 2026
Slide 1: Q2 FY26 Quarterly Company Call
Q2 FY26 QUARTERLY COMPANY CALL 29 January 2026 1
Slide 2: Q2 FY26 Key Highlights
Q2 FY26 KEY HIGHLIGHTS • CurveBeam AI received purchase orders (POs) for five (5) devices in Q2 FY26, four (4) of which were HiRise™, and one (1) LineUp. • Commercialisation agreements with Shandong WeiYing (WEGO Orthopaedics subsidiary) progressed to initial implementation steps and technology tran
Slide 3: Q2 FY26 Purchase Orders Analysis
Q2 FY26 PURCHASE ORDERS ANALYSIS TM Discontinued • Receipts from customers for Q2 FY26 were A$2.40m, down marginally from the comparative quarter result in FY25 (A$2.59m), while up 75% from the A$1.37m result in Q1 FY26. • The Company carried A$5.1m of purchase orders and receivables into Q2. With r
Slide 4: China Strategy Update for Q2 FY26
CHINA STRATEGY UPDATE FOR Q2 FY26 Company management attended the Annual Congress of Chinese Orthopaedic Association held 12-16 November 2025 in Tianjin, with WEGO Orthopaedics. HiRise™ was featured prominently on the stand, generating substantial interest. • The signing of the agreement triggered t
Slide 5: Enhanced HiRise Project for Robotic Aided Surgical Systems
ENHANCED HIRISE™ PROJECT FOR ROBOTIC AIDED SURGICAL SYSTEMS • The Company engaged with senior vendor executives on 13 Jan 2026 to align on the final data requirements for validating HiRise™ compatibility with their robotic surgery system, marking a significant step forward. • A definitive validation
Slide 6: BMD SaaS MDCT Module Update
BMD SAAS MDCT MODULE UPDATE Multidetector CT (MDCT) • During the quarter, the Company submitted its application for FDA clearance of the bone mineral density (BMD) Multiple Detector CT (MDCT) software module, under the FDA’s 510(k) Class II regulatory pathway. This FDA clearance is being targeted fo
Slide 7: Q2 FY26 Cash Analysis
Q2 FY26 CASH ANALYSIS: • Cashflows used in operations for Q2 FY26 was (A$2.15m) versus negative cash from operations of (A$4.00m) in Q1 FY26. Receipts from customers for Q2 FY26 were A$2.40m. • While the quarter closed with a cash balance of A$4.03m, the first milestone payment from WEGO Orthopaedic
Slide 8: Definitions
DEFINITIONS CurveBeam AI’s key metrics are defined and interpreted as follows: • Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time. • Receipts from customers – any cash consideration rec